| Literature DB >> 29662554 |
Karolina A Chodkowska1, Anna Ciecierska1, Kinga Majchrzak1, Piotr Ostaszewski1, Tomasz Sadkowski1.
Abstract
BACKGROUND: Skeletal muscle injury activates satellite cells to initiate processes of proliferation, differentiation, and hypertrophy in order to regenerate muscle fibers. The number of microRNAs and their target genes are engaged in satellite cell activation. β-Hydroxy-β-methylbutyrate (HMB) is known to prevent exercise-induced muscle damage. The purpose of this study was to evaluate the effect of HMB on miRNA and relevant target gene expression in differentiating equine satellite cells exposed to H2O2. We hypothesized that HMB may regulate satellite cell activity, proliferation, and differentiation, hence attenuate the pathological processes induced during an in vitro model of H2O2-related injury by changing the expression of miRNAs.Entities:
Keywords: Equine satellite cells; HMB; Muscle injury; Skeletal muscle; miRNA
Year: 2018 PMID: 29662554 PMCID: PMC5892041 DOI: 10.1186/s12263-018-0598-2
Source DB: PubMed Journal: Genes Nutr ISSN: 1555-8932 Impact factor: 5.523
Fig. 1Equine satellite cell culture. a Proliferating ESC, day 4. b Proliferating ESC, day 8. c Myotubes in differentiating ESC, day 2
Fig. 2H2O2 dose-dependent effect on ESC cell viability assessed by MTT assay
Fig. 3Experimental design. a Control group. b HMB-treated group
Primers for real-time qPCR: primers for miRNA
| No. | Primer’s name | Target sequence | Amplification time and temperature |
|---|---|---|---|
| 1 | miR-146a-5p | UGAGAACUGAAUUCCAUGGGUU | 10 s/95 °C and 60 s/60 °C |
| 2 | miR-146b-5p | UGAGAACUGAAUUCCAUAGGCU | 10 s/95 °C and 60 s/60 °C |
| 3 | miR-204b | UUCCCUUUGUCAUCCUAUGCCU | 10 s/95 °C and 60 s/60 °C |
| 4 | miR-208b | AUAAGACGAACAAAAGGUUUGU | 10 s/95 °C and 60 s/60 °C |
| 5 | miR-222 | AGCUACAUCUGGCUACUGGGU | 10 s/95 °C and 60 s/60 °C |
| 6 | miR-675 | UGGUGCGGAGAGGGCCCACAGUG | 10 s/95 °C and 60 s/60 °C |
Primers for real-time qPCR: primers for mRNA
| No. | Primer’s name | Forward sequence | Reverse sequence | Annealing time and temperature |
|---|---|---|---|---|
| 1 |
| CCACCTCCTGCAGAACAAAAG | GGGTCTTGGTAAAGGCTCATT | 15 s/60 °C |
| 2 | TGCTGCGAACCTACATCATC | CGATGACGTTCAAGGCAAGA | 15 s/60 °C | |
| 3 |
| GTCACCGAGGAGAAGTACCA | CTGGTTAGGACAGGCAACAA | 15 s/60 °C |
| 4 |
| GATTCCACGTCCACGAGTTT | CCCGAGAGTGAGATCACAGA | 15 s/60 °C |
| 5 |
| AGTACTACGCCAAGGAGGTT | TAGGCGGGATGGCATTTTCC | 15 s/60 °C |
| 6 |
| GGAGACGCCTGAAGAAAGTC | CCGGCAGGCTGTAGTAATTC | 15 s/60 °C |
| 7 |
| CCCCATGAAAGAAGCAAACG | TACAAGTCCGCGTCCTTACT | 15 s/60 °C |
| 8 |
| GTTTGTGATGGGCGTGAACC | GTCTTCTGGGTGGCAGTGAT | 15 s/60 °C |
MiRNAs differentially expressed in HMB-incubated equine satellite cells exposed to H2O2, compared to control
| No. | Name | Regulation | FC ([HMB] vs [CTRL]) | Log FC ([HMB] vs [CTRL]) | FDR | miRBase accession no. |
|---|---|---|---|---|---|---|
| 1 | eca-miR-146a | Up | 120.92 | 6.92 | 2.74E−18 | MIMAT0013065 |
| 2 | eca-miR-146b-5p | Up | 2.68 | 1.42 | 9.66E−07 | MIMAT0012891 |
| 3 | eca-miR-204b | Up | 1.74 | 0.79 | 3.26E−03 | MIMAT0013112 |
| 4 | eca-miR-222 | Up | 1.60 | 0.68 | 7.79E−04 | MIMAT0013204 |
| 5 | eca-miR-155 | Up | 1.49 | 0.57 | 2.30E−03 | MIMAT0013182 |
| 6 | eca-miR-193a-3p | Up | 1.39 | 0.47 | 9.29E−06 | MIMAT0013026 |
| 7 | eca-miR-221 | Up | 1.38 | 0.46 | 2.11E−03 | MIMAT0013203 |
| 8 | eca-miR-101 | Up | 1.34 | 0.42 | 2.10E−05 | MIMAT0012951 |
| 9 | eca-miR-142-3p | Down | 105.23 | − 6.72 | 2.81E−16 | MIMAT0013023 |
| 10 | eca-miR-675 | Down | 97.37 | − 6.60 | 1.71E−17 | MIMAT0013053 |
| 11 | eca-miR-486-5p | Down | 2.21 | − 1.14 | 2.95E−10 | MIMAT0013186 |
| 12 | eca-miR-542-5p | Down | 2.10 | − 1.07 | 1.71E−03 | MIMAT0013237 |
| 13 | eca-miR-149 | Down | 1.86 | − 0.89 | 4.68E−10 | MIMAT0012973 |
| 14 | eca-miR-206 | Down | 1.66 | − 0.73 | 1.76E−06 | MIMAT0013098 |
| 15 | eca-miR-208b | Down | 1.66 | − 0.74 | 1.50E−08 | MIMAT0012900 |
| 16 | eca-miR-133a | Down | 1.62 | − 0.70 | 4.99E−09 | MIMAT0012997 |
| 17 | eca-miR-133b | Down | 1.59 | − 0.67 | 8.26E−09 | MIMAT0013097 |
| 18 | eca-miR-128 | Down | 1.58 | − 0.66 | 1.19E−04 | MIMAT0013076 |
| 19 | eca-miR-542-3p | Down | 1.53 | − 0.61 | 5.92E−06 | MIMAT0013238 |
| 20 | eca-miR-1 | Down | 1.49 | − 0.57 | 2.86E−05 | MIMAT0012994 |
| 21 | eca-miR-324-5p | Down | 1.49 | − 0.58 | 3.75E−07 | MIMAT0013033 |
| 22 | eca-miR-450c | Down | 1.49 | − 0.58 | 2.86E−05 | MIMAT0013222 |
| 23 | eca-miR-450a | Down | 1.44 | − 0.53 | 1.19E−05 | MIMAT0013219 |
| 24 | eca-miR-532-3p | Down | 1.44 | − 0.53 | 1.02E−07 | MIMAT0013236 |
| 25 | eca-miR-331 | Down | 1.37 | − 0.46 | 1.60E−07 | MIMAT0013188 |
| 26 | eca-miR-374b | Down | 1.34 | − 0.42 | 2.81E−02 | MIMAT0013214 |
| 27 | eca-miR-30c | Down | 1.31 | − 0.39 | 2.41E−07 | MIMAT0012915 |
FDR ≤ 0.05, FC ≥ 1.3, n = 8
Fig. 4Identified miRNAs and their involvement in some selected physiological and pathological processes. MiRNAs in blue clouds were RT-qPCR-validated
Fig. 5Expression of selected miRNAs (a) and genes (b) validated by RT-qPCR. Presented values are means ± SE (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001). HMB—cells treated with HMB and exposed to H2O2. CTRL—cells without HMB treatment, exposed to H2O2 (n = 6)
Selected biological processes in which identified differentially expressed target genes (DET) were involved
| Category | Term | Count | FDR |
|---|---|---|---|
| GOTERM_BP_DIRECT | Skeletal muscle tissue development | 5 | 5.4E0 |
| GOTERM_BP_DIRECT | Regulation of inflammatory response | 5 | 7.6E0 |
| GOTERM_BP_DIRECT | Positive regulation of protein catabolic process | 5 | 1.7E1 |
| GOTERM_BP_DIRECT | Actin filament organization | 5 | 2.5E1 |
| GOTERM_BP_DIRECT | Positive regulation of Notch signaling pathway | 4 | 3.6E1 |
| GOTERM_BP_DIRECT | Protein ubiquitination involved in ubiquitin-dependent protein catabolic process | 7 | 3.7E1 |
| GOTERM_BP_DIRECT | Muscle cell cellular homeostasis | 3 | 4.5E1 |
| GOTERM_BP_DIRECT | Regulation of apoptotic process | 7 | 5.0E1 |
Fig. 6Degradation of protein in H2O2-treated cell cultures
Fig. 7Effect of HMB on cell viability measured by SYTOX Red Cell Dead assay (a) and MTT assay (b). Each value is the mean ± standard error of the results (n = 3, SYTOX Red Cell Dead assay; n = 6, MTT assay). Statistical analysis was performed using the one-way ANOVA (p < 0.05) and unpaired t test (p < 0.05) for SYTOX Red Cell Dead and MTT assay, respectively. H2O2—cells without HMB treatment and exposed to H2O2. H2O2 + HMB—cells treated with HMB and exposed to H2O2
Fig. 8Effect of HMB on oxidative stress—CellROX® Green assay (a) and Lipid peroxidation assay (b). Each value is the mean ± standard error of the results (n = 3, CellROX® Green assay; n = 6, lipid peroxidation assay). Statistical analysis was performed using the one-way ANOVA (p < 0.05) and unpaired t test (p < 0.05) for CellROX® Green assay and lipid peroxidation assay, respectively. H2O2—cells without HMB treatment and exposed to H2O2. H2O2 + HMB—cells treated with HMB and exposed to H2O2
Fig. 9Qualitative flow cytometry assay for mitochondrial depolarization (a) and total antioxidant capacity (TAC) (b). Each value is the mean ± standard error of the results (n = 3, JC-1 assay; n = 6, TAC assay). Statistical analysis was performed using the one-way ANOVA (p < 0.05) and unpaired t test (p < 0.05) for JC-1 assay and TAC assay, respectively. H2O2—cells without HMB treatment and exposed to H2O2. H2O2 + HMB—cells treated with HMB and exposed to H2O2
Selected differentially expressed genes (DEG, with the highest FC) and biological processes which they were involved in
| No. | Gene symbol | Regulation | Fold change | Description | Accession number | Related processes |
|---|---|---|---|---|---|---|
| 1 |
| Up | 76.31 | [ENSECAT00000010991] | Expressed in regenerating muscle | |
| 2 |
| Up | 52.29 | [NM_001114940] | Acute inflammation | |
| 3 |
| Up | 20.00 | [NM_001082496] | Mediates the generation and elimination of ROS, stimulates SCs proliferation and hypertrophy | |
| 4 |
| Up | 19.41 | [NM_001081931] | Acute inflammation | |
| 5 |
| Up | 17.95 | [NM_001081798] | Oxidative stress, enhances cell viability | |
| 6 |
| Up | 16.80 | [NM_001163892] | Acute phase response in skeletal muscle | |
| 7 |
| Up | 11.74 | [NM_001081863] | MAPK cascade, chronic inflammatory response | |
| 8 |
| Up | 11.66 | [NM_001081871] | Smooth muscle cell migration, chronic inflammatory response | |
| 9 |
| Up | 9.38 | [NM_001082517] | Oxidative stress | |
| 10 |
| Up | 7.80 | XIAP-associated factor 1 | [ENSECAT00000026936] | Apoptosis |
| 11 |
| Up | 7.20 | Poly(ADP-ribose) polymerase family member 14 | [ENSECAT00000026964] | Muscle metabolism |
| 12 |
| Up | 6.31 | Gasdermin d | [ENSECAT00000015748] | Necrosis in inflammation, cell proliferation, induce apoptosis |
| 13 |
| Up | 5.83 | [NM_001163883] | Participate in the proliferation of activated satellite cells via the Ras–Raf–MEK–ERK signaling pathway | |
| 14 |
| Up | 5.14 | Janus kinase 2 | [ENSECAT00000010434] | Response to injury |
| 15 |
| Up | 5.05 | [NM_001081902] | Humoral and cell-mediated immune responses, effective immune activation | |
| 16 |
| Up | 4.93 | Caspase 7 | [JL623025] | Muscle cell proliferation/survival |
| 17 |
| Up | 4.81 | Proteasome (prosome, macropain) subunit, beta type, 9 | [ENSECAT00000017937] | Muscle cell differentiation |
| 18 |
| Up | 4.10 | [NM_001287267] | Muscle cell differentiation |
Selected biological processes identified in DAVID for differentially expressed target genes (DET)
| No. | Biological processes | Number of identified genes | List of genes | FDR |
|---|---|---|---|---|
| 1 | Muscle organ development | 17 | 8.3E−03 | |
| 2 | Modification-dependent protein catabolic process | 27 | 1.4E−01 | |
| 3 | Muscle cell differentiation | 11 | 2.5E−01 | |
| 4 | Proteolysis involved in cellular catabolic process | 27 | 2.8E−01 | |
| 5 | Muscle tissue development | 11 | 3.3E−01 | |
| 6 | Protein catabolic process | 27 | 4.8E−01 | |
| 7 | Proteolysis | 37 | 1.6E−00 | |
| 8 | Regulation of apoptosis | 29 | 4.5E−00 | |
| 9 | Positive regulation of cellular biosynthetic process | 25 | 8.3E−00 | |
| 10 | Positive regulation of cell proliferation | 16 | 2.7E−01 | |
| 11 | Positive regulation of inflammatory response | 4 | 3.1E−01 |
Selected pathways identified in DAVID for differentially expressed target genes (DET) and their corresponding miRNAs
| No. | Pathway | Pathway | Number of genes | Gene name | Fold change | FDR | DET-related identified miRNA |
|---|---|---|---|---|---|---|---|
| 1 | RIG-I-like receptor signalling pathway | 5.2E−04 | 8 |
| 1.59 ↑ | 1.15E−2 | miR-101 ↑, |
|
| 1.31 ↑ | 1.11E−2 | |||||
|
| 56.62 ↑ | 2.16E−5 |
| ||||
|
| 1.78 ↑ | 1.19E−3 | |||||
|
| 2.27 ↑ | 2.44E−3 | miR-155↑, | ||||
|
| 1.68 ↑ | 5.43E−3 | |||||
|
| − 1.58 ↓ | 4.02E−3 | miR-30↓, | ||||
|
| 1.88 ↑ | 9.59E−3 | miR-101↑, | ||||
| 2 | Hyper-trophy cardiomyopathy | 1.5E−03 | 8 |
| − 1.42 ↓ | 1.10E−3 | |
|
| − 1.91 ↓ | 4.43E−3 | miR-142-3p↓, | ||||
|
| − 1.32 ↓ | 7.08E−3 | miR-30↓, | ||||
|
| − 1.49 ↓ | 6.71E−3 | miR-142-3p↓ | ||||
|
| − 1.69 ↓ | 5.03E−3 | miR-30↓, | ||||
|
| 1.33 ↑ | 1.34E−3 |
| ||||
|
| − 1.85 ↓ | 2.02E−4 | miR-142-3p↓, | ||||
|
| − 2.87 ↓ | 1.08E−2 | |||||
| 3 | MAPK signalling pathway | 7.3E−03 | 13 |
| − 2.08 ↓ | 9.14E−4 | miR-1↓, miR-206↓, |
|
| − 1.42 ↓ | 1.10E−3 | |||||
|
| 1.77 ↑ | 2.80E−3 | |||||
|
| 1.50 ↑ | 1.34E−3 | |||||
|
| − 1.36 ↓ | 1.11E−2 | miR-331↓ | ||||
|
| 5.83 ↑ | 2.33E−3 | miR-101↑, miR-155↑, | ||||
|
| 1.68 ↑ | 5.43E−3 | |||||
|
| − 1.58 ↓ | 4.02E−3 | miR-30↓, | ||||
|
| − 1.36 ↓ | 9.06E−3 | |||||
|
| 1.72 ↑ | 2.44E−3 | miR-221/222↑ | ||||
|
| 2.27 ↑ | 1.39E−3 |
| ||||
|
| 2.82 ↑ | 1.47E−3 |
| ||||
|
| − 1.62 ↓ | 9.09E−3 | miR-208↓, | ||||
| 4 | p38 MAPK | 9.9E−02 | 4 |
| 1.68 ↑ | 5.43E−3 | |
|
| − 1.36 ↓ | 9.01E−3 | |||||
|
| −1.58 ↓ | 4.02E−3 | miR-30↓, | ||||
|
| 1.77 ↑ | 2.80E−3 | |||||
| 5 | Toll-like receptor signalling pathway | 1.6E−02 | 7 |
| 1.31 ↑ | 1.11E−2 | miR-30↓, |
|
| 56.62 ↑ | 2.16E−5 |
| ||||
|
| 14.20 ↑ | 9.51E−5 | |||||
|
| 1.44 ↑ | 9.52E−4 | |||||
|
| 2.27 ↑ | 2.44E−3 | miR-155↑, | ||||
|
| 1.68 ↑ | 5.43E−3 | |||||
|
| − 1.58 ↓ | 4.02E−3 | miR-30↓, | ||||
| 6 | Ubiquitin-mediated proteolysis | 2.0E−02 | 8 |
| − 1.62 ↓ | 9.15E−3 | |
|
| − 1.71 ↓ | 4.76E−5 | |||||
|
| 1.58 ↑ | 1.08E−3 | miR-133a/b↓, | ||||
|
| − 1.40 ↓ | 1.01E−2 | miR-374↓, miR-542-3p↓ | ||||
|
| − 1.30 ↓ | 1.00E−2 | miR-30↓, miR-128↓ | ||||
|
| 1.50 ↑ | 1.13E−2 | miR-155↑, | ||||
|
| − 1.41 ↓ | 5.46E−4 | |||||
|
| − 1.53 ↓ | 3.80E−3 | miR-1↓, miR-206↓, | ||||
| 7 | Ras pathway | 3.4E−02 | 6 |
| − 1.44 ↓ | 3.27E−3 |
|
|
| − 1.54 ↓ | 9.09E−3 | |||||
|
| 1.98 ↑ | 7.19E−3 | miR-193↑, miR-208↑, miR-101↑, miR-221/222↑, | ||||
|
| 1.68 ↑ | 5.43E−3 | |||||
|
| − 1.58 ↓ | 4.02E−3 | miR-30↓, | ||||
|
| − 1.36 ↓ | 9.01E3 | |||||
| 8 | Oxidative stress response | 3.9E−02 | 5 |
| 1.77 ↑ | 2.80E−3 | |
|
| − 1.55 ↓ | 2.09E−3 |
| ||||
|
| 1.68 ↑ | 5.43E−3 | |||||
|
| − 1.36 ↓ | 9.01E−3 | |||||
|
| 2.27 ↑ | 1.39E−3 |
|
MiRNAs in bold have the opposite expression change to corresponding DET. The arrows indicate the direction of expression change: ↓ and ↑ for down- and upregulation, respectively
Fig. 10Potential role of HMB-induced miRNAs and selected target genes in muscle regeneration process